A French study has concluded that Proleukin (Interleukin-2, IL-2) does not appear to increase the likelihood of developing either Hodgkin’s disease (HD) or non-Hodgkin’s lymphoma (NHL), debunking some concerns that this possible immune-based therapy may be associated with a greater risk of these life-threatening cancers. The encouraging data were published online January 7 in the Journal of Acquired Immune Deficiency Syndromes.
Missed visits to the doctor in the first year of HIV care may double the risk of death, according to a study published in the January 15 issue of Clinical Infectious Diseases.
Starting antiretroviral (ARV) treatment before CD4 counts drop to 350 or below results in the restoration of immune cell numbers to near normal levels in people with HIV, according to a study published online January 5 in Clinical Infectious Diseases.